<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article188</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/APROCCHSS" style="display:block; margin-bottom:10px;">APROCCHSS Original</a></li>
<h2><strong>APROCCHSS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In adult patients with septic shock, does the addition of hydrocortisone plus fludrocortisone therapy result in reduced all-cause mortality at 90 days?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In adult patients with septic shock, the addition of hydrocortisone plus fludrocortisone significantly reduced 90-day all-cause mortality compared to placebo. <br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of 2018, there are varying guidelines regarding the use of corticosteroids in septic shock. This trial may inform future updates to these guidelines.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized trial<br/>
- N=1,241 adult patients with septic shock<br/>
- Hydrocortisone (50mg IV q6h) plus fludrocortisone (50 Î¼g tablet once daily) vs. placebo<br/>
- Primary outcome: 90-day all-cause mortality<br/>
- Secondary outcomes: Mortality at ICU discharge, hospital discharge, day 28, and day 180; number of days alive and free of vasopressors, mechanical ventilation, or organ failure<br/>
- Intervention period: 7 days without tapering<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Adult ICU patients with septic shock for less than 24 hours<br/>
- Exclusion Criteria: Septic shock for at least 24 hours, high bleeding risk, pregnancy or lactation, life-threatening comorbidities, hypersensitivity to the study drugs, or previous corticosteroid therapy<br/>
- Baseline Characteristics: Similar across groups, with most patients having severe septic shock, high severity-of-illness scores, and community-acquired infections<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients received hydrocortisone plus fludrocortisone therapy or placebo for 7 days<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: 90-day mortality was 43.0% in the treatment group vs. 49.1% in the placebo group (P=0.03)<br/>
- Secondary Outcomes: <br/>
  - Lower mortality at ICU and hospital discharge in the treatment group<br/>
  - Shorter time to weaning from vasopressors and mechanical ventilation in the treatment group<br/>
  - More vasopressor-free and organ-failure-free days in the treatment group<br/>
- No significant difference in secondary infections or gastrointestinal bleeding, but higher risk of hyperglycemia in the treatment group<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The trial was underpowered to assess the effect of drotrecogin alfa (activated) after its withdrawal from the market<br/>
- The imbalance in the distribution of pathogens, with slightly more viral infections in the treatment group<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health (contract P070128)<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full text is available on The New England Journal of Medicine website
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
